Amyotrophic Lateral Sclerosis (ALS) Market Outlook

Thelansis’s “Amyotrophic Lateral Sclerosis (ALS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2026 To 2036” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Amyotrophic Lateral Sclerosis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Amyotrophic Lateral Sclerosis (ALS) Overview

Amyotrophic lateral sclerosis (ALS) is a relentlessly progressive and invariably fatal neurodegenerative disease characterised by selective loss of both upper and lower motor neurons in the cortex, brainstem, and spinal cord, leading to progressive muscular paralysis and ultimately respiratory failure. The underlying pathophysiology is multifactorial and incompletely understood, encompassing aberrant protein aggregation — notably TDP-43 and SOD1 misfolding — glutamate-mediated excitotoxicity, mitochondrial dysfunction, neuroinflammation, and impaired axonal transport; approximately 10% of cases are familial, with mutations in SOD1, C9orf72, FUS, and TARDBP among the most clinically significant, while the majority are sporadic with complex gene-environment interactions implicated. Patients typically present with insidious focal weakness — either limb-onset with progressive distal wasting and fasciculations, or bulbar-onset with dysarthria, dysphagia, and sialorrhoea — alongside upper motor neuron signs including spasticity, hyperreflexia, and pathological reflexes; cognitive and behavioural changes consistent with frontotemporal involvement are increasingly recognised in a substantial subset. Diagnosis remains clinical, guided by the revised El Escorial or Gold Coast criteria, supported by electromyography demonstrating widespread active and chronic denervation, with neuroimaging and genetic testing serving to exclude mimics and identify heritable variants. Disease-modifying options remain limited; riluzole, a glutamate antagonist, modestly extends survival, while edaravone and more recently tofersen — an antisense oligonucleotide targeting SOD1 — represent incremental therapeutic advances in defined patient subgroups. Multidisciplinary care is the unequivocal standard, encompassing respiratory support with non-invasive ventilation, nutritional optimisation via gastrostomy, augmentative communication strategies, spasticity and pain management, and psychological support for patients and caregivers alike. Median survival from symptom onset is two to four years, though considerable heterogeneity exists; early and proactive advance care planning, goals-of-care discussions, and hospice integration are essential components of compassionate, patient-centred management that honours individual values and preserves dignity throughout the disease course.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2026–2036)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)